Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-2 of 2

Sort by

Sort Order Select

Journal Articles

Venetoclax dosages, BH3 profiling, and bcl-2 expression predict response to azacitidine + venetoclax regimen in first line AML not eligible to intensive chemotherapy: First results of venetacible study

Thomas Cluzeau, Cecile Favreau, Maxence Bourgoin, Geoffroy Venton, Raphaelle Fanciullino, Melanie Boucher, Caroline Fileni, Sami Benachour, Michael Loschi, Berengere Dadone-Montaudie, Patrick Auberger, Arnaud Jacquel, Guillaume Robert

Blood (2025) 146 (Supplement 1): 5250.

https://doi.org/10.1182/blood-2025-5250

Published: 2025

Journal Articles

Oral azacitidine maintenance improved survival for t-AML or AML-MR patients in first remission after CPX-351 and not eligible to HSCT

Caroline Fileni, David Swoboda, Alexander Coltoff, Najla Al Ali, Rami Komrokji, Onyee Chan, Geoffrey Uy, Sarah Bertoli, Alessandro Isidori, Lenaig Le Clech, Mael Heiblig, Ludovic Gabellier, Patrick Lawrence, Lydia Kretschmer, Christoph Röllig, Jeffrey Lancet, Andrew Wei, David Sallman, Thomas Cluzeau

Blood (2025) 146 (Supplement 1): 3441.

https://doi.org/10.1182/blood-2025-3441

Published: 2025